A detailed history of Bank Of America Corp transactions in Atara Biotherapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 6,580,577 shares of ATRA stock, worth $50.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,580,577
Previous 189,128 3379.43%
Holding current value
$50.7 Million
Previous $96,000 4629.17%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$0.44 - $1.22 $2.81 Million - $7.8 Million
6,391,449 Added 3379.43%
6,580,577 $4.54 Million
Q4 2023

Feb 14, 2024

BUY
$0.23 - $1.74 $24,791 - $187,556
107,791 Added 132.52%
189,128 $96,000
Q2 2023

Aug 14, 2023

SELL
$1.5 - $3.04 $1.7 Million - $3.44 Million
-1,132,963 Reduced 93.3%
81,337 $130,000
Q1 2023

May 12, 2023

BUY
$2.8 - $5.46 $2.35 Million - $4.57 Million
837,836 Added 222.55%
1,214,300 $3.52 Million
Q4 2022

Feb 10, 2023

SELL
$2.85 - $5.18 $305,397 - $555,073
-107,157 Reduced 22.16%
376,464 $1.23 Million
Q3 2022

Nov 14, 2022

BUY
$2.85 - $8.73 $390,971 - $1.2 Million
137,183 Added 39.6%
483,621 $1.83 Million
Q2 2022

Aug 12, 2022

BUY
$4.69 - $9.84 $750,643 - $1.57 Million
160,052 Added 85.87%
346,438 $2.7 Million
Q1 2022

May 16, 2022

BUY
$8.44 - $16.89 $527,660 - $1.06 Million
62,519 Added 50.47%
186,386 $1.73 Million
Q4 2021

Feb 08, 2022

BUY
$14.7 - $19.89 $921,939 - $1.25 Million
62,717 Added 102.56%
123,867 $1.95 Million
Q3 2021

Nov 15, 2021

BUY
$11.99 - $17.9 $262,197 - $391,437
21,868 Added 55.67%
61,150 $1.09 Million
Q2 2021

Sep 13, 2021

BUY
$12.89 - $16.58 $506,344 - $651,295
39,282 New
39,282 $611,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $728M
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.